Home  »  Companies   »  ADMA Biologics Inc. (ADMA) Reveals an Earnings Mys...

ADMA Biologics Inc. (ADMA) Reveals an Earnings Mystery

ADMA Biologics Inc. (NASDAQ:ADMA) went down by -2.17% from its latest closing price compared to the recent 1-year high of $3.47.

Is It Worth Investing in ADMA Biologics Inc. (NASDAQ :ADMA) Right Now?

Plus, the 36-month beta value for ADMA is at 0.98. Opinions of the stock are interesting as 4 analysts out of 4 who provided ratings for ADMA Biologics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored

The average price from analysts is $5.00, which is $1.84 above the current price. ADMA currently public float of 176.84M and currently shorts hold a 14.63% ratio of that float. Today, the average trading volume of ADMA was 3.06M shares.

ADMA’s Market Performance

ADMA stocks went down by 0.00% for the week, with a monthly jump of 15.75% and a quarterly performance of 17.91%, while its annual performance rate touched 124.11%. The volatility ratio for the week stands at 3.61% while the volatility levels for the past 30 days are set at 5.53% for ADMA Biologics Inc. The simple moving average for the period of the last 20 days is 8.52% for ADMA stocks with a simple moving average of 43.81% for the last 200 days.

Analysts’ Opinion of ADMA

Many brokerage firms have already submitted their reports for ADMA stocks, with Mizuho repeating the rating for ADMA by listing it as a “Buy.” The predicted price for ADMA in the upcoming period, according to Mizuho is $5 based on the research report published on October 13th of the current year 2022.

Raymond James, on the other hand, stated in their research note that they expect to see ADMA reach a price target of $5. The rating they have provided for ADMA stocks is “Strong Buy” according to the report published on November 11th, 2021.

Cantor Fitzgerald gave a rating of “Overweight” to ADMA, setting the target price at $4.50 in the report published on November 09th of the previous year.

ADMA Trading at 16.60% from the 50-Day Moving Average

After a stumble in the market that brought ADMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.93% of loss for the given period.

Volatility was left at 5.53%, however, over the last 30 days, the volatility rate increased by 3.61%, as shares surge +12.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.49% upper at present.

During the last 5 trading sessions, ADMA remain unchanged, which changed the moving average for the period of 200-days by +92.68% in comparison to the 20-day moving average, which settled at $2.93. In addition, ADMA Biologics Inc. saw 124.11% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for ADMA

Current profitability levels for the company are sitting at:

  • -72.41 for the present operating margin
  • +0.57 for the gross margin

The net margin for ADMA Biologics Inc. stands at -88.52. Equity return is now at value -58.30, with -23.80 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 6.87.

Is CVS Health Corporation (CVS) a Keeper?

CVS Health Corporation (NYSE:CVS) went up by 0.55% from its latest closing price compared to the recent 1-year high of $111.25. The company’s stock price

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]